Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Cumberland Pharmaceuticals IncCPIX-1.880.410.5812.69-32.99%-2.33%36.43$1.31$3.354,007$1.12

Detail of Cumberland Pharmaceuticals Inc

 
CEO
Mr. A. J. Kazimi MBA
Employees
91
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$16M

Company details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$38.83M
Cost of goods (CoG)
-$6.39M
Gross profit (GP)
$32.43M
Operating expense (OE)
-$34.34M
Research and development (R&D)
-$5.49M
General and administrative (G&A)
-$28.85M
Operating income (OI)
-$9.89M
Other income expense (OIE)
-$1.80M
Pretax income (PI)
-$8.36M
Tax (TAX)
-$50,273.00
Net income (NI)
-$8.41M
Cumberland Pharmaceuticals Inc
CPIX • XNGS • US
$1.12
-0.88 (-44.00%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.60
Margin profit
-27.46%
52 week low
$1.12
52 week high
$2.24
50-day simple moving average
$1.25
200-day simple moving average
$1.31
Percent held by insiders
44.47%
Percent held by institutions
14.87%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CPIX -44.55%
eps change
CPIX -1,500.00%